Characterization of clinically relevant RNA alterations for personalized cancer medicine

Trincado Alonso, Juan Luis

Characterization of clinically relevant RNA alterations for personalized cancer medicine

Document Type

Doctoral thesis
Published Version

Author

Trincado Alonso, Juan Luis

Director

Eyras Jiménez, Eduardo

Publication Date

2019-01-28

Pages

143 p.

Citation

Trincado Alonso, J. Characterization of clinically relevant RNA alterations for personalized cancer medicine. Universitat Pompeu Fabra; 2019. handle: http://hdl.handle.net/10803/665991

This citation was generated automatically.

Doctoral program

Programa de doctorat en Biomedicina

Abstract

The following thesis tries to answer the question of wheter RNA processing alterations are informative for the clinical management of cancer patients. For this, the work is focused on solve two main issues: the development of computational tools to study RNA profiles from multiple tumors and the identification of RNA-related signatures that may be predictive of prognosis and therapy. The thesis is divided in three chapters: First, the development a new tool for fast quantification of differential splicing: SUPPA2. Second, a new methodology for elucidating the prognostic potential of alternative transcript isoforms across human tumours. And third, a new method for the detection of aberrant tumor splicing junctions and their antigenic evaluation.
La presente tesis intenta arrojar luz sobre la pregunta de si las alteraciones del ARN son informativas para el tratamiento clínico de pacientes con cancer. Para ello, este trabajo se centra en resolver dos cuestiones principales: el desarrollo de metodos computaciones para el estudio de perfiles de ARN en multiples tumores y la identificación de marcadores que puedan ser predictivos de prognosis y terapia. La tesis está dividida en tres capítulos: Primero, el desarollo de un nuevo método para la cuantificación rápida de splicing diferencial: SUPPA2. Segundo, una nueva metodologia para dilucidar el potencial prognóstico de tránscritos alternativos en tumores humanos. Y tercero, un nuevo método para la detección de junctions aberrantes tumorales y su evaluacion antigénica